Skip to main content
Up to 53% offSee the plans

News | Stocks | Iran

Iran Antibiotic Manufacturing (IAMZ) More Than Doubles Six-Month Profit to 3,152 Billion Rials on 19% Revenue Growth, Close to All of Fiscal 1404

Sahmino Newsroom | 19 November 2026 | yesterday

IAMZup3.0%46,090rials18 November

In its standalone income statement for the six months to 31 Shahrivar 1405 (22 September 2026), filed on Codal on 18 November 2026, Iran Antibiotic Manufacturing (IAMZ) reported operating revenue of 10,376 billion rials, up 19% from 8,743 billion rials in the same period a year earlier (restated).

Cost of sales was almost flat, up 2% to 5,480 billion rials, so gross profit grew 44% to 4,896 billion rials and the gross margin rose from 38.8% to 47.2%. Operating profit is 4,802 billion rials (up 45%), while finance costs went from 444 billion rials to 749 billion rials.

Current-year income tax fell from 1,422 billion rials to 982 billion rials and net profit reached 3,152 billion rials, 119% above 1,442 billion rials in the same period a year earlier. Basic earnings per share went from 1,799 to 3,934 rials, and the six-month profit equals 98% of the full-year profit for fiscal 1404 (3,209 billion rials). Share capital is 803 billion rials.

Reference:CodalThe original report

Sahmino context

What the prices have done since this story was published, and what Sahmino wrote around it

More from this market